All posts by David Weinberg

David Weinberg is a retired academic vitreoretinal surgeon. He is emeritus Professor of Ophthalmology and Visual Science at the Medical College of Wisconsin. His interest in the less-than-science-based aspects of medicine was sparked by inquiries from his patients. Investigation their questions led to his discovery of numerous grandiose claims for implausible, unproven treatments of potentially blinding eye diseases. All opinions expressed by Dr. Weinberg are his alone, and do not represent those of his employer or any other organization with which he is affiliated.

Author

  • David Weinberg is a retired academic vitreoretinal surgeon. He is emeritus Professor of Ophthalmology and Visual Science at the Medical College of Wisconsin. His interest in the less-than-science-based aspects of medicine was sparked by inquiries from his patients. Investigation their questions led to his discovery of numerous grandiose claims for implausible, unproven treatments of potentially blinding eye diseases. All opinions expressed by Dr. Weinberg are his alone, and do not represent those of his employer or any other organization with which he is affiliated.

A person holding a large, shiny, metallic-looking rock with both hands. The rock appears rough and glittery, resembling a lump of pyrite or "fool's gold.

A department adrift from its own “Gold” standards

Phantom citations, misinformation, and imbalance in HHS communications

/ July 29, 2025
Several gold bars are stacked, but one bar is cut open to reveal a gray, rough interior, indicating that it is not solid gold.
An orange prescription pill bottle with a white cap labeled "Truth, Power, and the Drugs You Take" appears under the large title "Rethinking Medications" by Jerry Avorn, MD, Professor of Medicine, Harvard Medical School.

Rethinking Medications: Truth, Power, and the Drugs You Take

A critical appraisal of the state of the prescription medications in the United States

/ May 28, 2025
Timeline of the Diabetes Prevention Program & Outcomes Study from 1996 to present. Sections include Intensive Lifestyle, Metformin, and Placebo, transitioning to modified interventions and lifestyle sessions over time, ending with ongoing lifestyle education.

The tragic termination of the Diabetes Prevention Program Outcomes Study

An invaluable resource is being starved to death with no scientific or ethical justification

/ April 1, 2025

The use of placebo controls in clinical trials

Why the value of placebo controls is not an affirmation of a powerful placebo effect

/ March 20, 2025
Image of a USAID notification announcing a reduction-in-force affecting 1,600 personnel. Starting February 23, 2025, all direct hire personnel will be on administrative leave, except for specific designations.

Indiscriminate, Cruel, and Wasteful: Abandoning USAID clinical trials

The chaos and cruelty of its abrupt deconstruction are self-evident and already demonstrable

/ February 25, 2025
A person wearing white gloves holds several small Botox vials with purple, pink, and blue caps, labeled with various brands. The vials appear to contain injectable solutions.

Botulinum Toxin: A tale of medicine, beauty, and danger

When used responsibly botulinum toxin is very safe, but patients should be especially vigilant about cosmetic treatments done outside a medical setting.

/ February 10, 2025
Woman holding baby away from doctor trying to give shot.

We are not antivaccine, we are pro unattainable vaccine

When it comes to vaccines: “If it exists we resist.” 

/ February 6, 2025
Macular degeneration

Pegcetacoplan (Syfovre™) for macular degeneration: an update

SBM's guest contributor and ophthalmologist, Dr. David Weinberg, provides an update on the phase 3 trials of pegcetacoplan for macular degeneration. The results are still disappointing.

/ January 11, 2024

Pegcetacoplan, a new treatment for macular degeneration

FDA approves a new treatment for macular degeneration: the good, the bad, and the disappointing.

/ June 6, 2023